Article Text

Download PDFPDF

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry
  1. M Carpelan-Holmström1,
  2. S Nordling2,
  3. E Pukkala3,
  4. R Sankila3,
  5. J Lüttges4,
  6. G Klöppel4,
  7. C Haglund1
  1. 1Department of Surgery, Helsinki University Central Hospital, Finland
  2. 2Department of Pathology, Helsinki University Central Hospital, Finland
  3. 3Finnish Cancer Registry, Helsinki, Finland
  4. 4Department of Pathology, University of Kiel, Germany
  1. Correspondence to:
    Dr C Haglund
    Department of Surgery, Helsinki University Central Hospital, Finland PO Box 340, Helsinki, Fin-00029, Finland; caj.haglundhus.fi

Abstract

Background: Worldwide survival data for ductal adenocarcinoma of the pancreas are the lowest among the 60 most frequent types of organ cancers. Hence published data on long time survivors of this disease are controversial. We performed a nationwide study comprising all Finnish patients diagnosed with pancreatic cancer in the period 1990–1996 who survived for at least five years after diagnosis.

Methods: Data on patients registered as five year survivors of pancreatic cancer were obtained from the Finnish Cancer Registry and Statistics Finland. Slides or paraffin blocks were collected from patients recorded as having histologically proven pancreatic ductal adenocarcinoma (PDAC) and were re-evaluated in a double blind fashion by three pathologists with special expertise in pancreatic pathology.

Results: Between 1990 and 1996, the Finnish Cancer Registry recorded 4922 pancreatic cancer patients, 89 of whom survived for at least five years. Reviewing this series of patients revealed 45 (49%) non-PDACs and 18 cases without histological verification. In 26 patients recorded as having histologically proven PDAC, re-evaluation of histological specimens confirmed PDAC in only 10 patients.

Conclusions: This study indicates that (1) the prognosis of PDAC remains poor and (2) careful histopathological review of all patients with pancreatic cancer is mandatory if survival data are to be meaningful.

  • PDAC, pancreatic ductal adenocarcinoma
  • pancreatic ductal adenocarcinoma
  • Finnish Cancer Registry
  • histopathology
  • pancreas
  • survival
View Full Text

Statistics from Altmetric.com

Footnotes

  • Conflict of interest: None declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.